BeiGene wants to ensure access to medicines for all patients and puts patients first in the fight against cancer. We foster strong collaborations that extend to the furtherest reaches of the globe. Learn more about the BeiGene story.

The panel answers questions from the audience at the ESH 2021 satellite symposium providing insight into treatment considerations with different Bruton's tyrosine kinase inhibitors (BTKis) for Waldenström's macroglobulinemia (WM) patients.

Professor Véronique LeBlond introduces the satellite symposium at ESH 2021 and outlines the learning objectives for the session on how BTK inhibition is a key approach to managing and treating indolent lymphomas.

Dr Benjamin Besse discusses targeting other components of immune checkpoint including TIGIT, TIM-3 and OX40 in immunotherapy combinations.

Dr Riyaz Shah discusses alternative PD-1 inhibitors as the backbones for immunotherapy combinations.